Suraksha Diagnostic Intrinsic Value
Suraksha Diagnostic (SURAKSHA) median intrinsic value is ₹210.00 from 9 valuation models (range ₹98–₹815), vs current price ₹325.80 — -35.5% downside (Trading Above Calculated Value), margin of safety -55.1%. Compare with SURAKSHA DCF valuation to assess whether the stock is under or overvalued.
SURAKSHA Valuation Methods Summary — DCF, Graham Number & P/E
Suraksha Diagnostic intrinsic value across 9 models vs current price ₹325.80 — upside/downside and value range per method. For current market price and key ratios, visit Suraksha Diagnostic share price screener.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹97.74 | ₹78.19 - ₹117.29 | -70.0% | EPS: ₹6.92, Sector P/E: 12x |
| Book Value Method | asset | ₹210.00 | ₹189.00 - ₹231.00 | -35.5% | Book Value/Share: ₹210.00, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹256.00 | ₹230.40 - ₹281.60 | -21.4% | Revenue/Share: ₹320.00, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹600.00 | ₹540.00 - ₹660.00 | +84.2% | EBITDA: ₹100.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹814.50 | ₹651.60 - ₹977.40 | +150.0% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹97.74 | ₹87.97 - ₹107.51 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹97.74 | ₹87.97 - ₹107.51 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 8.2x |
| ROE Based Valuation | profitability | ₹504.00 | ₹453.60 - ₹554.40 | +54.7% | ROE: 17.1%, P/E Multiple: 14x |
| Graham Defensive Method | conservative | ₹180.82 | ₹162.74 - ₹198.90 | -44.5% | EPS: ₹6.92, BVPS: ₹210.00 |
SURAKSHA Intrinsic Value vs Market Price — All Valuation Models
Suraksha Diagnostic fair value range ₹98–₹815 vs current market price ₹325.80 across 9 valuation models. Read SURAKSHA dividend growth for the complete payout history and dividend yield track record.
SURAKSHA Intrinsic Value Analysis — Undervalued or Overvalued?
Suraksha Diagnostic median intrinsic value ₹210.00, current price ₹325.80 — Trading Above Calculated Value by 35.5%, margin of safety -55.1%.
What is the intrinsic value of SURAKSHA?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Suraksha Diagnostic (SURAKSHA) is ₹210.00 (median value). With the current market price of ₹325.80, this represents a -35.5% variance from our estimated fair value.
The valuation range spans from ₹97.74 to ₹814.50, indicating ₹97.74 - ₹814.50.
Is SURAKSHA undervalued or overvalued?
Based on our multi-method analysis, Suraksha Diagnostic (SURAKSHA) appears to be trading above calculated value by approximately 35.5%.
SURAKSHA Financial Health — Key Ratios vs Industry Benchmarks
Suraksha Diagnostic financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 0.58 | Industry Standard: 2.0+ | Below 1.5 | Measures short-term liquidity capacity |
| Return on Equity | 17.1% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 31.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.96x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
SURAKSHA Cash Flow Quality — Operating & Free Cash Flow
Suraksha Diagnostic operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹63 Cr | ₹43 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹61 Cr | ₹44 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹44 Cr | ₹34 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹42 Cr | ₹20 Cr | Positive Free Cash Flow | 7/10 |
| March 2021 | ₹24 Cr | ₹10 Cr | Positive Free Cash Flow | 7/10 |